1. Home
  2. AMSF vs CRGX Comparison

AMSF vs CRGX Comparison

Compare AMSF & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AMSF
  • CRGX
  • Stock Information
  • Founded
  • AMSF 1985
  • CRGX 2021
  • Country
  • AMSF United States
  • CRGX United States
  • Employees
  • AMSF N/A
  • CRGX N/A
  • Industry
  • AMSF Accident &Health Insurance
  • CRGX
  • Sector
  • AMSF Finance
  • CRGX
  • Exchange
  • AMSF Nasdaq
  • CRGX Nasdaq
  • Market Cap
  • AMSF 968.5M
  • CRGX 964.5M
  • IPO Year
  • AMSF 2005
  • CRGX 2023
  • Fundamental
  • Price
  • AMSF $53.78
  • CRGX $20.37
  • Analyst Decision
  • AMSF Buy
  • CRGX Strong Buy
  • Analyst Count
  • AMSF 2
  • CRGX 7
  • Target Price
  • AMSF $59.50
  • CRGX $30.33
  • AVG Volume (30 Days)
  • AMSF 123.3K
  • CRGX 162.3K
  • Earning Date
  • AMSF 10-23-2024
  • CRGX 11-21-2024
  • Dividend Yield
  • AMSF 8.33%
  • CRGX N/A
  • EPS Growth
  • AMSF N/A
  • CRGX N/A
  • EPS
  • AMSF 3.21
  • CRGX N/A
  • Revenue
  • AMSF $315,182,000.00
  • CRGX N/A
  • Revenue This Year
  • AMSF N/A
  • CRGX N/A
  • Revenue Next Year
  • AMSF N/A
  • CRGX N/A
  • P/E Ratio
  • AMSF $16.75
  • CRGX N/A
  • Revenue Growth
  • AMSF 2.81
  • CRGX N/A
  • 52 Week Low
  • AMSF $41.97
  • CRGX $13.14
  • 52 Week High
  • AMSF $56.46
  • CRGX $33.92
  • Technical
  • Relative Strength Index (RSI)
  • AMSF 63.17
  • CRGX 49.30
  • Support Level
  • AMSF $50.12
  • CRGX $19.10
  • Resistance Level
  • AMSF $55.28
  • CRGX $22.56
  • Average True Range (ATR)
  • AMSF 1.20
  • CRGX 1.41
  • MACD
  • AMSF 0.23
  • CRGX -0.13
  • Stochastic Oscillator
  • AMSF 62.04
  • CRGX 30.38

About AMSF AMERISAFE Inc.

AMERISAFE Inc is a specialty provider of workers' compensation insurance to employers engaged in hazardous industries, mainly construction, trucking, manufacturing, oil and gas, and agriculture. The company generates a majority of its revenue in the form of premiums.

About CRGX CARGO Therapeutics Inc.

Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.

Share on Social Networks: